Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT05626322 · Pfizer · PHASE1/PHASE2 · terminated · last registry update 2025-09-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD19 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-18Results posted on the registry: Kite, A Gilead Company, Fludarabine + Cyclophosphamide (NCT04880434)
- 2026-08-10Results posted on the registry: NeoImmuneTech, Efineptakin alfa + Tisagenlecleucel (NCT05075603)
- 2026-07-23Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, BLB101 for Injection + Blinatumomab for Injection (NCT07723911)
- 2026-07-22Also stopped (withdrawn): University of Pennsylvania, CD19 redirected autologous T cells (CTL019 or CTL119 cells) (NCT04419909)
- 2026-07-20Also stopped (terminated): ADC Therapeutics S.A., Loncastuximab Tesirine (NCT05660395)
- 2026-06-25Results posted on the registry: University of Washington, Acalabrutinib + Axicabtagene Ciloleucel (NCT04257578)
- 2026-06-15Also stopped (terminated): University of Washington, Loncastuximab Tesirine (NCT05453396)
- 2026-06-09Results posted on the registry: University of California, Davis, Blinatumomab + Ibrutinib (NCT02997761)
- 2026-05-20Phase 3 first posted: Amgen, Inebilizumab + Placebo (NCT07598825)
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-04-07Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Epcoritamab + Lenalidomide (NCT07030699)
- 2026-03-18Phase 3 first posted: Kite, A Gilead Company, KITE-753 + Axicabtagene Ciloleucel (NCT07479797)
- 2026-03-18Also stopped (withdrawn): Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Cyclophosphamide + Doxorubicin (NCT06313996)
- 2026-03-17Phase 3 first posted: Charite University, Berlin, Germany, Inotuzumab ozogamicin (INO) + Blinatumomab (NCT07476729)
- 2026-03-10Results posted on the registry: Amgen, inebilizumab + IV Placebo (NCT04524273)
- 2026-03-10Results posted on the registry: Kite, A Gilead Company, Brexucabtagene Autoleucel + Cyclophosphamide (NCT05537766)
- 2026-03-10Also stopped (terminated): Kite, A Gilead Company, Brexucabtagene Autoleucel + Cyclophosphamide (NCT05537766)
- 2026-03-06Also stopped (terminated): Imugene Limited, CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy (NCT06063317)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2026-02-27Also stopped (terminated): Jonsson Comprehensive Cancer Center, Anakinra + Axicabtagene Ciloleucel (NCT04205838)
- 2026-02-04Also stopped (terminated): Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-01-29Results posted on the registry: Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-01-29Results posted on the registry: Patrick C. Johnson, MD, ACALABRUTINIB + LISOCABTAGENE MARALEUCEL (NCT05583149)
- 2026-01-23Results posted on the registry: Masonic Cancer Center, University of Minnesota, KYMRIAH + YESCARTA (NCT03642626)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision